APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer

Not Applicable

Recruiting

• Conditions: Prostate Cancer

• Registration Number: NCT06709326
• Lead Sponsor: Umeå University

Brief Summary

The goal of this clinical study is to to improve diagnosis, follow-up and treatment for patients with disseminated prostate cancer.

The aim is to isolate tumour cells before image diagnostic methods find the metastases. In addition, investigators will use this method to characterise the tumour cells at the "single-cell" level to understand both the metastasis process, early resistance mechanisms and thus find new treatment targets to optimise individualised treatment.

Research subjects who either have disseminated disease at diagnosis or have recurrence after surgery (with minimal dissemination) will be included. A control population of young men without cancer will also be recruited to distinguish tumor-specific changes from normal signals using these new methods.

Detailed Description

In this prospective clinical study, led by Umeå University, all research subjects will undergo apheresis and subjects with cancer will also undergo multiple radiological examinations to both identify apheresis and subsequent experimental protocols for isolation of tumor cells, immune cells and other components from the blood. The goal is to increase the sensitivity of identifying circulating tumor cells in early-stage metastatic prostate cancer for molecular characterization without biopsies of metastases. By doing this on multiple occasions in primary metastatic prostate cancer, investigators will identify early resistance mechanisms to given treatment and also investigate immune changes to standard treatment of metastatic prostate cancer (castration). Through qualitative approach, investigators will identify healthy and risk factors for managing the diagnosis of metastatic prostate cancer and the experience of undergoing apheresis to identify circulating tumor cells (CTC) in the blood, with the aim of identifying possible risks for mental health with this research.

Study Timeline

• Study Start: 2020-09-29
• Study First Submitted: 2023-03-17
• Status Verified: 2024-10
• Study First Submitted QC: 2024-11-26
• Last Update Submitted: 2024-11-26
• Study First Posted: 2024-11-28
• Last Update Posted: 2024-11-28
• Primary Completion: 2025-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 130

Inclusion Criteria

-The patient (arm 1 and arm 2) must have a health status that minimises the already low risks of the apheresis treatment, have the logistical possibilities to come to the visits according to the study and be planned for treatment according to standard treatment in Sweden today.

For arm 1, 2 and 3:

• Venous blood vessels enabling apheresis
• ECOG-performance status 0-2
• Concentration of av potassium, calcium and magnesium in blood within normal range
• Testosterone>1,7 nmol/L
• Hb>90 g/L
• TPK >50x10exp9 /L
• LPK >1x10exp9 /L
• Bilirubin <1,4 x upper limit for normal (unless the subject suffers from Gilberts disease)
• ALAT or ASAT <2,4 x above limit for normal
• Creatinine <2 mg/dL (<177µmol/L)

Additional inclusion criteria for Arm 1 - Metastatic prostate cancer

One of the following criteria:

• PSA >100ng/ml
• Skeletal metastases with high risk of prostate cancer (regardless of PSA-value)

Additional inclusion criteria for Arm 2 - PSA relapse after operation

All of the three following criteria must be fulfilled:

• Prostatectomy
• PSA >0.2ng/ml
• PSA doubling time <18 months (according to www.mskcc.org/nomograms/prostate/psa_doubling_time)

Additional inclusion criteria for Arm 3 - Healthy research subjects (control group)

All of the following two criteria must be fulfilled:

• Previously healthy (no ongoing medication)
• No history of cancer

Exclusion Criteria for arm 1, 2 and 3:

• Overall, research subjects must not have any other cancer disease or risk factors for undergoing apheresis treatment
• Weight <50 kg
• Medical castration last 6 months (or previous surgical castration)
• Antiandrogen treatment in the last 6 months
• Previous myocardial infarction, stroke, chronic heart failure, atrial fibrillation or multiple deep vein thromboses
• Heart rate <45
• Systolic blood pressure below 100
• Ongoing diagnosed chronic inflammation

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Identify circulating tumor cells (CTC) for molecular characterization	At inclusion in the study and after 4 weeks of treatment.	Identification of circulating tumor cells will be accomplished by RNA-based phenotyping using lineage specific transcripts.
Differentiated gene expression in CTCs before and after treatment start	At inclusion in the study and after 4 weeks of treatment.	To find resistance mechanisms by deep molecular characterization of CTC before and after treatment start to identify up and down regulations of genes in paired samples.
Phenotypical changes of immune cells due to anti-androgen treatment	At inclusion in the study, after 4 weeks of treatment, after 3, 6 and 12 months of treatment.	Broad molecular characterization of immune cells before initiation of treatment and at different time points after anti-androgen treatment

Secondary Outcome Measures

Name	Time	Method
Progression free survival	Within 24, 48 and 72 months respectively	Time to progression defined as PSA relapse or new metastasis or prostate cancer death, which ever comes first.

Trial Locations

Locations (1)

Department of surgical and perioperative sciences, Umeå university; 🇸🇪 Umeå, Norrlands University Hospital, Sweden